144 related articles for article (PubMed ID: 27179128)
21. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.
Stirnimann G
Expert Opin Pharmacother; 2014 Dec; 15(17):2609-22. PubMed ID: 25347030
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.
Khatri A; Dutta S; Marbury TC; Preston RA; Rodrigues L; Wang H; Awni WM; Menon RM
Clin Pharmacokinet; 2017 Feb; 56(2):153-163. PubMed ID: 27389403
[TBL] [Abstract][Full Text] [Related]
23. Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
Polepally AR; Badri PS; Eckert D; Mensing S; Menon RM
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):333-339. PubMed ID: 27165046
[TBL] [Abstract][Full Text] [Related]
24. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV
J Viral Hepat; 2018 Oct; 25(10):1180-1188. PubMed ID: 29660224
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
[TBL] [Abstract][Full Text] [Related]
26. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
Lalezari J; Sullivan JG; Varunok P; Galen E; Kowdley KV; Rustgi V; Aguilar H; Felizarta F; McGovern B; King M; Polepally AR; Cohen DE
J Hepatol; 2015 Aug; 63(2):364-9. PubMed ID: 25839406
[TBL] [Abstract][Full Text] [Related]
27. Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination.
Gamal N; Andreone P
Drugs Today (Barc); 2015 May; 51(5):303-14. PubMed ID: 26097903
[TBL] [Abstract][Full Text] [Related]
28. Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir.
Schnell G; Tripathi R; Beyer J; Reisch T; Krishnan P; Dekhtyar T; Irvin M; Hall C; Yu Y; Mobashery N; Redman R; Pilot-Matias T; Collins C
J Viral Hepat; 2018 Sep; 25(9):1078-1088. PubMed ID: 29624809
[TBL] [Abstract][Full Text] [Related]
29. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
Schnell G; Tripathi R; Krishnan P; Beyer J; Reisch T; Irvin M; Dekhtyar T; Setze C; Rodrigues L; Alves K; Burroughs M; Redman R; Chayama K; Kumada H; Collins C; Pilot-Matias T
J Med Virol; 2018 Jan; 90(1):109-119. PubMed ID: 28842997
[TBL] [Abstract][Full Text] [Related]
30. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
31. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.
Vince B; Hill JM; Lawitz EJ; O'Riordan W; Webster LR; Gruener DM; Mofsen RS; Murillo A; Donovan E; Chen J; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Zhou XJ
J Hepatol; 2014 May; 60(5):920-7. PubMed ID: 24434503
[TBL] [Abstract][Full Text] [Related]
32. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
Liu CH; Liu CJ; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2018 Mar; 33(3):710-717. PubMed ID: 28762541
[TBL] [Abstract][Full Text] [Related]
33. Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct-acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin.
Fedorchenko SV; Martynovych T; Klimenko Z; Yanchenko V; Solianyk I
J Viral Hepat; 2020 May; 27(5):548-551. PubMed ID: 31894886
[TBL] [Abstract][Full Text] [Related]
34. Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.
Gopalakrishnan SM; Polepally AR; Mensing S; Khatri A; Menon RM
Clin Pharmacokinet; 2017 Jan; 56(1):1-10. PubMed ID: 27314261
[TBL] [Abstract][Full Text] [Related]
35. Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.
Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Zhang X; Setze C; Rodrigues L; Burroughs M; Redman R; Chayama K; Kumada H; Collins C; Pilot-Matias T
Antimicrob Agents Chemother; 2016 Feb; 60(2):1106-13. PubMed ID: 26643326
[TBL] [Abstract][Full Text] [Related]
36. Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.
Gopalakrishnan S; Khatri A; Mensing S; Redman R; Menon R; Zha J
Adv Ther; 2016 Apr; 33(4):670-83. PubMed ID: 27084721
[TBL] [Abstract][Full Text] [Related]
37. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
DeGoey DA; Randolph JT; Liu D; Pratt J; Hutchins C; Donner P; Krueger AC; Matulenko M; Patel S; Motter CE; Nelson L; Keddy R; Tufano M; Caspi DD; Krishnan P; Mistry N; Koev G; Reisch TJ; Mondal R; Pilot-Matias T; Gao Y; Beno DW; Maring CJ; Molla A; Dumas E; Campbell A; Williams L; Collins C; Wagner R; Kati WM
J Med Chem; 2014 Mar; 57(5):2047-57. PubMed ID: 24400777
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.
Krishnan P; Beyer J; Mistry N; Koev G; Reisch T; DeGoey D; Kati W; Campbell A; Williams L; Xie W; Setze C; Molla A; Collins C; Pilot-Matias T
Antimicrob Agents Chemother; 2015 Feb; 59(2):979-87. PubMed ID: 25451055
[TBL] [Abstract][Full Text] [Related]
39. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
Sulkowski MS; Eron JJ; Wyles D; Trinh R; Lalezari J; Wang C; Slim J; Bhatti L; Gathe J; Ruane PJ; Elion R; Bredeek F; Brennan R; Blick G; Khatri A; Gibbons K; Hu YB; Fredrick L; Schnell G; Pilot-Matias T; Tripathi R; Da Silva-Tillmann B; McGovern B; Campbell AL; Podsadecki T
JAMA; 2015 Mar 24-31; 313(12):1223-31. PubMed ID: 25706092
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
Pockros PJ; Reddy KR; Mantry PS; Cohen E; Bennett M; Sulkowski MS; Bernstein DE; Cohen DE; Shulman NS; Wang D; Khatri A; Abunimeh M; Podsadecki T; Lawitz E
Gastroenterology; 2016 Jun; 150(7):1590-1598. PubMed ID: 26976799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
